Turalio® (pexidartinib) is the
first and only oral therapy for
tenosynovial giant cell tumor (TGCT)

Turalio is a medication that blocks some of the inflammation signals that can cause TGCT.

Turalio is used to treat certain adults who have TGCT that is not likely to improve with surgery.

Turalio is not chemotherapy.

Turalio is a medication that blocks some of the inflammation signals that can cause TGCT.

Turalio was studied in a clinical trial of 120 patients who had advanced TGCT, for whom surgery was not recommended.

For 24 weeks, half of the patients in the trial were given Turalio and half were given a placebo. After 24 weeks, patients in both groups were offered continued treatment with Turalio.

The study tested whether
Turalio was able to:

 
Down arrow icon

Eliminate or reduce tumor size

Up arrow icon

Increase joint movement

The clinical trial included TGCT in both the upper and lower body

The image below shows the locations of patients’ tumors in the trial (120 patients).

Image showing the location of patients’ tumors in the clinical trial

Of patients in the trial:

diffuse-TGCT No-surgery-for-TGCT diffuse-TGCT No-surgery-for-TGCT-mob

Turalio: Clinically proven to help reduce tumor size

Two measurements tracked whether Turalio was able to reduce the size of the patients’ tumors. One measured the length of the tumor. The other measured the volume of the tumor (the amount of space the tumor filled within the joint).

Results with Turalio

When measuring by tumor length, 38% people saw their tumors get smaller or disappear completely after 6 months with Turalio

Of the patients taking Turalio:

  • 23% (14 of 61) had their tumors reduce in length by 30% or more
  • 15% (9 of 61) had their tumors disappear completely

No patient taking placebo experienced a reduction in tumor length.

When measuring by tumor length, 61% of people saw their tumors get smaller at completion of the trial at ~5.5 years

Of the patients taking Turalio:

  • 61% (37 of 61) had their tumors reduce in length by 30% or more
Tumor size management
Tumor volume management

When measuring by tumor volume, 56% of people saw their tumors get smaller by half or more after 6 months with Turalio

Of the patients taking Turalio:

  • 51% (31 of 61) had their tumors reduce in volume by 50% or more
  • 5% (3 of 61) had their tumors disappear completely

No patient taking placebo experienced a reduction in tumor length.

When measuring by tumor volume, 68% of people saw their tumors get smaller at completion of the trial at ~5.5 years

Of the patients taking Turalio:

  • 68% of patients (62 of 91) had their tumors reduce in volume by 50% or more

People taking Turalio had significantly improved range of motion compared to patients taking placebo at 25 weeks

Range of motion is a measure of the amount of movement possible in a specific joint.

Joints studied in the trial included:

  • Knees (25 on Turalio vs 28 on placebo)
  • Ankles (11 on Turalio vs 7 on placebo)
  • Other (9 on Turalio vs 8 on placebo)

Information was not available for 16 of 61 patients in the Turalio arm and 16 of 59 patients in the placebo arm. It was not possible to know if the patients with data missing were experiencing worse range of motion than patients with data available.

Range of motion with Turalio
Turalio patient icon

Most Turalio patients showed reduction in tumor volume of 50% or more.

I’ve been on Turalio for 16 months. I don’t know what the future holds, but I’m optimistic.

–Siobhan

Siobhan, Turalio patient and brand ambassador since 2021
Siobhan, Turalio patient and brand ambassador since 2021
plant image

A comprehensive guide to Turalio

Learn about Turalio dosing and more.

Download the patient brochure

Preparing to take Turalio

Discover the first and only treatment of its kind for TGCT.

Learn how to prepare